Detalhe da pesquisa
1.
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
N Engl J Med
; 389(3): 239-250, 2023 Jul 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37212440
2.
Antibody NI006 for Cardiac Transthyretin Amyloid Depletion. Reply.
N Engl J Med
; 389(13): 1249, 2023 Sep 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37754296
3.
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
N Engl J Med
; 378(7): 615-624, 2018 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29231094
4.
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
Am Heart J
; 235: 132-139, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33493453
5.
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 140(22): 1792-1801, 2019 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31597460
6.
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Circulation
; 139(6): 760-771, 2019 02 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30586727
7.
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 40(19): 1541-1550, 2019 05 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30624719
8.
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 40(19): 1518-1527, 2019 05 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30590425
9.
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 138(18): 1963-1973, 2018 10 30.
Artigo
Inglês
| MEDLINE | ID: mdl-29967197
10.
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
Europace
; 21(2): 306-312, 2019 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30462220
11.
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
Eur Heart J
; 38(12): 888-896, 2017 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-28064150
12.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Lancet
; 388(10055): 1995-2003, 2016 Oct 22.
Artigo
Inglês
| MEDLINE | ID: mdl-27590218
13.
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke
; 47(8): 2075-82, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27387994
14.
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet
; 385(9984): 2280-7, 2015 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25769357
15.
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Lancet
; 385(9984): 2288-95, 2015 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25769361
16.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med
; 369(15): 1406-15, 2013 Oct 10.
Artigo
Inglês
| MEDLINE | ID: mdl-23991658
17.
Edoxaban versus warfarin in patients with atrial fibrillation.
N Engl J Med
; 369(22): 2093-104, 2013 Nov 28.
Artigo
Inglês
| MEDLINE | ID: mdl-24251359
18.
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Am Heart J
; 172: 144-51, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26856226
19.
Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillationã- An ENGAGE AF-TIMI 48 Subanalysis.
Circ J
; 80(4): 860-9, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26888149
20.
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Vasc Med
; 21(4): 361-8, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27165711